The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 15, 2018

Filed:

Dec. 19, 2016
Applicant:

Eisai R&d Management Co., Ltd., Tokyo, JP;

Inventors:

Yoshimasa Sakamoto, Nishinomiya, JP;

Yusuke Adachi, Tsukuba, JP;

Junji Matsui, Tsukuba, JP;

Yu Kato, Tsukuba, JP;

Yoichi Ozawa, Tsukuba, JP;

Takanori Abe, Tsukubamirai, JP;

Ken Ito, Kashiwa, JP;

Yuya Nakazawa, San Diego, CA (US);

Sho Tachino, Tsukuba, JP;

Katsuhisa Suzuki, Tsukubamirai, JP;

Kishan Agarwala, Tsukuba, JP;

Kana Hoshino, Kobe, JP;

Masahiko Katayama, Fujieda, JP;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C07K 14/705 (2006.01); C07K 16/32 (2006.01); A61K 31/337 (2006.01); A61K 31/47 (2006.01); A61K 33/24 (2006.01); C12N 9/14 (2006.01); C07K 14/71 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/32 (2013.01); A61K 31/337 (2013.01); A61K 31/47 (2013.01); A61K 33/24 (2013.01); A61K 39/39558 (2013.01); C07K 14/705 (2013.01); C07K 16/28 (2013.01); C07K 16/303 (2013.01); C07K 16/3023 (2013.01); C12N 9/14 (2013.01); C12Y 301/03001 (2013.01); A61K 2039/505 (2013.01); C07K 2317/20 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2319/21 (2013.01); C07K 2319/42 (2013.01);
Abstract

The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of the mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of the mouse anti-human Notch4 antibody.


Find Patent Forward Citations

Loading…